Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Innovent Biologics, Inc. clinical trials
The registry lists 216 studies whose lead sponsor is Innovent Biologics, Inc. or one of 4 companies grouped under it. 59 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Innovent Biologics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Innovent Biologics, Inc..
- Innovent Biologics (Suzhou) Co. Ltd.197 studies →Subsidiary
Something wrong?
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.7 studies →Subsidiary
Something wrong?
- Innovent Biologics Technology Limited (Shanghai R&D Center)7 studies →Subsidiary
Something wrong?
- Fortvita Biologics (USA)Inc.5 studies →Regional office
Something wrong?
Focus areas
Conditions Innovent Biologics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 216. Browse all 216 →
- IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyNot yet recruitingNCT07886476Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of IBI3046 in Participants With Overweight or ObesityRecruitingNCT07809945Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty ArthritisNot yet recruitingNCT07842497Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07754786Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)RecruitingNCT07066098Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT06349408Phase 1
Sponsor listed in the registry: Fortvita Biologics (USA)Inc.
- Study of IBI3020 Treatment in Participants With Late-Stage Solid TumorsRecruitingNCT06963281Phase 1
Sponsor listed in the registry: Fortvita Biologics (USA)Inc.
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT07336472Phase 1/2
Sponsor listed in the registry: Fortvita Biologics (USA)Inc.
- A Study of IBI3042 in Healthy Adult ParticipantsNot yet recruitingNCT07842393Phase 1
Sponsor listed in the registry: Fortvita Biologics (USA)Inc.
- A Study of IBI3016 in Japanese ParticipantsRecruitingNCT07838220Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's DiseaseNot yet recruitingNCT07836660Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsRecruitingNCT07793019Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07643623Phase 2/3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese ParticipantsNot yet recruitingNCT07765160Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingNCT07764861Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye DiseaseRecruitingNCT07265258Phase 4
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRecruitingNCT07722494Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of IBI363 in Subjects With Advanced MelanomaRecruitingNCT06081920Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07122687Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsRecruitingNCT07589205Phase 1
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Clinical Trials of IBI3035 in Healthy SubjectsRecruitingNCT07591519Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of IBI3031 in Participants With Thyroid Eye DiseaseRecruitingNCT07622368Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Safety and Preliminary Activity of BI115 in Advanced SCLCRecruitingNCT07559019Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI343 in Combination Therapy for Advanced Malignant Solid TumorsRecruitingNCT07483554Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07483567Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruitingNCT07612137Phase 1/2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingNCT07469800Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT05458219Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose AdministrationRecruitingNCT07554222Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of IBI3033 in Moderate-to-Severe Atopic DermatitisNot yet recruitingNCT07549984Phase 1
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingNCT07490262Phase 2/3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- A Study of Picankibart in Patients With Active Psoriatic ArthritisRecruitingNCT07295509Phase 2/3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07330934Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerRecruitingNCT07377643Phase 3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT07399067Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung CancerNot yet recruitingNCT07402070Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid TumorsRecruitingNCT07327632Early Phase 1
Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)
- IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsRecruitingNCT06974812Phase 1/2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMDRecruitingNCT07275840Phase 2
Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)
- A Study of IBI362 in Chinese Adolescents With Obesity or OverweightRecruitingNCT07255209Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT07265284Phase 3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseaseRecruitingNCT07113262Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib ProgressionNot yet recruitingNCT07199010
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of IBI3032 in Healthy ParticipantsRecruitingNCT07120425Phase 1
Sponsor listed in the registry: Fortvita Biologics (USA)Inc.
- A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07124793Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain MetastasesRecruitingNCT07008287
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingNCT06931028Phase 3
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyRecruitingNCT06797297Phase 2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.
- A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT05636215Phase 1/2
Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.